These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29089307)

  • 1. CCGs face legal threat for offering off-label drug for wet AMD.
    Cohen D
    BMJ; 2017 Oct; 359():j5021. PubMed ID: 29089307
    [No Abstract]   [Full Text] [Related]  

  • 2. Why have UK doctors been deterred from prescribing Avastin?
    Cohen D
    BMJ; 2015 Apr; 350():h1654. PubMed ID: 25834024
    [No Abstract]   [Full Text] [Related]  

  • 3. A licence to cure.
    Aronson JK; Ferner RE
    BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
    [No Abstract]   [Full Text] [Related]  

  • 4. Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?
    Cohen D
    BMJ; 2017 Oct; 359():j5016. PubMed ID: 29089312
    [No Abstract]   [Full Text] [Related]  

  • 5. Commentary: NHS patients should have a choice of drug for wet age-related macular degeneration, despite pressure from pharma.
    Hambleton D
    BMJ; 2017 Oct; 359():j5013. PubMed ID: 29089330
    [No Abstract]   [Full Text] [Related]  

  • 6. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
    Torjesen I
    BMJ; 2012 Apr; 344():e2959. PubMed ID: 22532011
    [No Abstract]   [Full Text] [Related]  

  • 7. Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration.
    Hawkes N
    BMJ; 2012 Jul; 345():e5161. PubMed ID: 22846417
    [No Abstract]   [Full Text] [Related]  

  • 8. [An eye for an eye? Lack of consensus in off-label use of medications leads to major regional differences in medical costs for the treatment of wet AMD in Sweden].
    Bro T
    Lakartidningen; 2017 Nov; 114():. PubMed ID: 29292948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attacks on publicly funded trials: what happens when industry does not want to know the answer.
    Cohen D
    BMJ; 2015 Apr; 350():h1701. PubMed ID: 25834025
    [No Abstract]   [Full Text] [Related]  

  • 10. A clearer view of evidence in treating macular degeneration: off-label policies and independent research.
    Formoso G; Marata AM; Magrini N; Bero L
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):ED000090. PubMed ID: 25228121
    [No Abstract]   [Full Text] [Related]  

  • 11. Age-related macular degeneration: treatment at what cost?
    The Lancet
    Lancet; 2018 Sep; 392(10153):1090. PubMed ID: 30303068
    [No Abstract]   [Full Text] [Related]  

  • 12. Avastin and Lucentis: a guide through the legal maze.
    Lock D
    BMJ; 2015 Apr; 350():h1377. PubMed ID: 25834023
    [No Abstract]   [Full Text] [Related]  

  • 13. Why using Avastin for eye disease is so difficult.
    Torjesen I
    BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
    [No Abstract]   [Full Text] [Related]  

  • 14. Time to ask patients about drugs for macular degeneration.
    Mackenzie JW
    BMJ; 2017 Nov; 359():j5426. PubMed ID: 29184013
    [No Abstract]   [Full Text] [Related]  

  • 15. Roche and Novartis colluded over wet AMD drugs, says Italian regulator.
    Cohen D
    BMJ; 2014 Mar; 348():g2006. PubMed ID: 24615827
    [No Abstract]   [Full Text] [Related]  

  • 16. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I
    BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948
    [No Abstract]   [Full Text] [Related]  

  • 17. Legal. PCTs taken to court over use of cheaper drug.
    Calkin S
    Health Serv J; 2012 Apr; 122(6303):10-1. PubMed ID: 22741353
    [No Abstract]   [Full Text] [Related]  

  • 18. Perhaps the Avastin debate should be resolved in court.
    Fell G
    BMJ; 2015 Apr; 350():h2044. PubMed ID: 25901019
    [No Abstract]   [Full Text] [Related]  

  • 19. The GMC's stance on Avastin.
    Dickson N
    BMJ; 2015 Apr; 350():h2043. PubMed ID: 25898987
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost comparison of ranibizumab and bevacizumab.
    Jackson TL; Kirkpatrick L
    BMJ; 2011 Aug; 343():d5058. PubMed ID: 21862536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.